Press releases & news

 

2cureX provides update regarding the COVID-19 impact on ongoing clinical programs

2020-03-23

Press Releases Regulatory

Copenhagen — March 23, 2020 — 2cureX AB (“2cureX”, NASDAQ: 2CUREX) announced today that the corona-crisis will not delay 2cureX’s intervention study where the IndiTreat test is guiding treatment of patients with metastatic colorectal cancer (ClinicalTrials.gov Identifier: NCT03251612). Patient recruitment will continue as planned and finalization of the trial is expected as previously communicated in Q3 of 2020.

Vejle University Hospital has informed 2cureX that patient recruitment for the metastatic colorectal cancer trial will be upheld. The project is in its late stage and patient recruitment will continue as planned with finalization in Q3 2020.

The later started 2cureX clinical programs in ovarian cancer and pancreatic cancer will however be affected by delays. The length of these delays is not known presently.

2cureX has previously announced that IndiTreat will be introduced on the European market in second half of 2020. IndiTreat will initially be offered within the indication of colorectal cancer and is expected to launch as planned.

2cureX announced on March 12 that the company has taken the necessary precautions related to the COVID-19 outbreak. Tasks are now handled by employees working from home. Critical functions in our laboratories in both Copenhagen and Hamburg will continue.

Ole Thastrup, CEO comments:

“It is obvious that the COVID-19 pandemic has a major impact on all parts of society, including 2cureX. Within the directions of the Danish government it is however possible for 2cureX to keep all our important functions running including the IndiTreat testing on patient samples. It is very good news for colorectal cancer patients that they can still be offered the IndiTreat test in the ongoing clinical trial. With the present knowledge it is our expectation that the trial can be finalized as planned in the third quarter of 2020”.

For more information about 2cureX:
Ole Thastrup, Chief Executive Officer
E-mail: ot@2curex.com
Telephone: +45 2211 5399
www.2curex.com

Certified Adviser:
Svensk Kapitalmarknadsgranskning AB
Email: ca@skmg.se
Phone: +46 11 32 30 732

This information is information that 2cureX AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, on March 23, 2020.

 ——-

About 2cureX

2cureX has developed the IndiTreat® (Individual Treatment) test. IndiTreat® establishes thousands of 3D micro-tumours that are similar to the patient’s tumour and identifies the treatment that most effectively kills the patient’s tumor. Immediately after the test, the patient can be offered the selected treatment.

IndiTreat® is being clinically validated in clinical studies in colorectal cancer, ovarian cancer, pancreatic cancer and preventive cancer medicine. The clinical programs are conducted at major cancer hospitals in Denmark, Germany and United Kingdom.

IndiTreat® is presently being introduced into the European market through an Early Access Program.

The aspiration is that IndiTreat® becomes a standard tool in Precision Medicine for cancer patients.

The company is listed at the Nasdaq First North Growth Market in Stockholm (symbol “2CUREX”).

Contact information

2cureX, Fruebjergvej 3, 2100 Copenhagen Ø, Denmark| Phone: +45 2211 5399| E-mail: info@2curex.com

Privacy Policy | Imprint